SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Gimsing Peter))
 

Sökning: (WFRF:(Gimsing Peter)) > Melphalan and predn...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006882naa a2200709 4500
001oai:DiVA.org:uu-135021
003SwePub
008101203s2010 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:ff5230b1-5218-4eba-a93d-9e31032ed581
009oai:DiVA.org:umu-36855
009oai:DiVA.org:liu-59727
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-1350212 URI
0247 a https://doi.org/10.1182/blood-2009-08-2379742 DOI
0247 a https://lup.lub.lu.se/record/16978712 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-368552 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-597272 URI
040 a (SwePub)uud (SwePub)lud (SwePub)umud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Waage, Andersu Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway,NTNU4 aut
2451 0a Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
264 1b American Society of Hematology,c 2010
338 a print2 rdacarrier
520 a In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was 0.25 mg/kg and prednisone was 100 mg given daily for 4 days every 6 weeks until plateau phase. The dose of thalidomide/placebo was escalated to 400 mg daily until plateau phase and thereafter reduced to 200 mg daily until progression. A total of 357 patients were analyzed. Partial response was 34% and 33%, and very good partial response or better was 23% and 7% in the MPT and MP arms, respectively (P < .001). There was no significant difference in progression-free or overall survival, with median survival being 29 months in the MPT arm and 32 months in the MP arm. Most quality of life outcomes improved equally in both arms, apart from constipation, which was markedly increased in the MPT arm. Constipation, neuropathy, non-neuropathy neurologic toxicity, and skin reactions were significantly more frequent in the MPT arm. The number of thromboembolic events was equal in the 2 treatment arms. In conclusion, MPT had a significant antimyeloma effect, but this did not translate into improved survival. This trial was registered at www.clinicaltrials.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a MEDICINE
653 a MEDICIN
7001 a Gimsing, Peteru Department of Hematology, Rigshospitalet and University of Copenhagen4 aut
7001 a Fayers, Peteru Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway4 aut
7001 a Abildgaard, Nielsu Department of Hematology, Odense University Hospital, Odense, Denmark4 aut
7001 a Ahlberg, Luciau Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Hematologiska kliniken US4 aut0 (Swepub:liu)lucah64
7001 a Björkstrand, Bou Hematology Centre, Karolinska University Hospital/Huddinge, Stockholm, Sweden4 aut
7001 a Carlson, Kristinau Uppsala universitet,Medicin,Hematologi,Department of Hematology, Uppsala University Hospital, Uppsala, Sweden4 aut0 (Swepub:uu)krica965
7001 a Forsberg, Karinu Umeå universitet,Onkologi,Norrland University Hospital4 aut0 (Swepub:umu)nonkin02
7001 a Dahl, Inger Marieu Department of Medicine, University Hospital Tromsø, Tromsø, Norway4 aut
7001 a Gulbrandsen, Ninau Department of Hematology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway4 aut
7001 a Haukas, Einaru Department of Medicine, Stavanger University Hospital, Stavanger, Norway4 aut
7001 a Hjertner, Öyvindu Department of Hematology, St Olavs Hospital and Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway4 aut
7001 a Hjorth, Martinu Department of Hematology, Lidköping Hospital, Lidköping, Sweden4 aut
7001 a Karlsson, Torbjörnu Uppsala universitet,Medicin,Hematologi,Department of Internal Medicine, Capio Sankt Görans Hospital, Stockholm, Sweden4 aut0 (Swepub:uu)tokar839
7001 a Knudsen, Lene Meldgaardu Department of Hematology, Herlev Hospital, Copenhagen, Denmark4 aut
7001 a Nielsen, Johan Lanngu Department of Hematology, Aarhus University Hospital, Aarhus, Denmark4 aut
7001 a Linder, Olleu Department of Medicine, Örebro University Hospital, Örebro, Sweden4 aut
7001 a Mellqvist, Ulf-Henriku Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden4 aut
7001 a Nesthus, Ingeridu Department of Medicine, Haukeland University Hospital, Bergen, Norway4 aut
7001 a Rolke, Jurgenu Department of Medicine, Kristiansand Hospital, Kristiansand, Norway4 aut
7001 a Strandberg, Mariau Department of Medicine, Sundsvalls Hospital, Sundsvall, Sweden4 aut
7001 a Sörbo, Jon Hjalmaru Department of Medicine, Levanger Hospital, Levanger, Norway4 aut
7001 a Wislöff, Finnu Department of Hematology, Ullevål University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway4 aut
7001 a Juliusson, Gunnaru Lund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Lund University Hospital, Lund, Sweden4 aut0 (Swepub:lu)stem-gju
7001 a Turesson, Ingemaru Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine,Department of Medicine, Malmö University Hospital, Malmö, Sweden4 aut0 (Swepub:lu)medf-itu
7102 a Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norwayb NTNU4 org
7730 t Bloodd : American Society of Hematologyg 116:9, s. 1405-1412q 116:9<1405-1412x 0006-4971x 1528-0020
8564 u http://dx.doi.org/10.1182/blood-2009-08-237974y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-135021
8564 8u https://doi.org/10.1182/blood-2009-08-237974
8564 8u https://lup.lub.lu.se/record/1697871
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-36855
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-59727

Hitta via bibliotek

  • Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy